Home
Clinical Resources Search
PQI: Managing TKI-Induced Hand-Foot Skin Reaction

Managing TKI-Induced Hand-Foot Skin Reaction

Download PQI pdf 0.18MB

Last Updated: October 6, 2023

By: Jessie Modlin, PharmD, BCOP

About this PQI

Hand-foot skin reaction (HFSR) is one of the most common cutaneous adverse events caused by protein tyrosine kinase inhibitors (TKIs). It is important to prevent and manage this side effect in an effort to avoid dose reductions or treatment interruptions and reduced quality of life.

More About This PQI

PQI:

Medication-Induced-Hand-Foot-Syndrome_PQI_NCODA pdf 0.19MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Hand Foot Skin Reaction (HFSR) Hand Foot Syndrome Supportive Care

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Managing TKI-Induced Hand-Foot Skin Reaction

About this PQI

More About This PQI

PQI:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Medication Induced Hand-Foot Syndrome

PQI: Medication Induced Hand-Foot Syndrome

The PQI Podcast S4 Ep 5: Role of Oncology Social Worker

The PQI Podcast S4 Ep 6 : Community Pharmacy and Ohio Board of Pharmacy

The PQI Podcast S4 Ep 9: Mental Illness and Burnout

The PQI Podcast S4 Ep 10: Oncology Wellness & Exercise

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings